BioNTech To Acquire Neon to Bolster its Immunotherapy Pipeline
Shots:
- BioNtech to acquire Neon in an all-stock transaction for $67M or $2.18/ share of Neon based on the closing price of BioNTechs’ ADS of $34.55 & at a premium of 77.2% on 15 Jan- 2020. The transaction is expected to be closed in Q2’2020
- The focus of the acquisition is to expand BioNTech’s CAR-T and TCR therapy pipeline with the addition of Neon’s adoptive T cell and neoantigen TCR therapies including NEO-PTC-01- which complements BioNtech’s pipeline and focus on solid tumors
- The acquisition accelerates BioNtech’s presence in the US by creating a hub for research and clinical development. Neon’s NEO-PTC-01 is a T cell therapy targeting shared RAS neoantigens
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Neon therapeutics
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com